ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
55 announcements with these filters
Viyash Scientific announced postal ballot results. Shareholders approved the appointments of Amit Jain and Abhiroop Jayanthi as Non-Executive Directors.
Viyash Scientific shared its Investor Day presentation, outlining its integrated pharmaceutical strategy and leadership profile. No new financial or operational data were disclosed.
Viyash Scientific targets a $1Bn revenue platform by 2032 through the merger of Sequent and Viyash Life Sciences, focusing on animal and human health.
Viyash Scientific acquired 100% of Italy's BioForLife for ₹188 Crore. The strategic move strengthens its European companion animal health presence and global growth footprint.
Viyash Scientific acquired 100% of BioForLife Italia for €16.975 million (₹185.03 Crore). The acquisition strengthens the company's companion animal health presence in the Italian market.
Viyash Scientific Limited issued a postal ballot notice for director appointments and a one-time incentive. Shareholders will vote on a ₹4.00 Crore performance bonus.
Viyash Scientific Limited filed its Annual Secretarial Compliance Report for the year ended March 31, 2026. The report details regulatory compliance and historical governance observations.
India Ratings withdrew its rating on Viyash Scientific's ₹35 Crore bank facilities at the company's request. ICRA upgraded its rating to [ICRA] AA- (Stable).
Viyash reports a transformative Q4 FY26 with EBITDA surpassing ₹200cr. Revenue rose 19.1% YoY to ₹920cr, driven by integration synergies and a shift toward high-potent human and animal health products.
Viyash delivered a breakout FY26 with Q4 EBITDA crossing 200cr, marking a successful business integration.
Viyash Q4 FY26 revenue reached ₹9,200 Mn with 21.7% EBITDA margins. Management highlights successful integration and a deleveraged balance sheet.
Viyash Scientific reported FY26 revenues of ₹3,420.3 Crore, with PAT growing 1324%. Strong Q4 performance and merger synergies indicate a solid foundation for future growth.
Viyash Scientific Ltd reported revenue from operations of ₹920 Cr (+19.1% YoY) and net profit of ₹66.4 Cr for Q4 FY26.
Viyash Scientific approved its FY 2025-26 audited financial results and a new employee stock option scheme. No dividend was recommended to conserve resources for growth.
Viyash Scientific Limited reported the sad demise of Mr. Phillip Trott, AVP – Legal and Compliance. This senior management departure was effective as of May 15, 2026.
Viyash Scientific Ltd scheduled a board meeting for May 19, 2026, to approve fiscal 2026 audited financial results. The board will also consider recommending a dividend.
Viyash Scientific Limited received a credit rating upgrade from India Ratings and Research. The long-term rating for INR 35 Crore bank facilities improved to 'IND AA-' with a Stable outlook from 'IND A', while the short-term rating was upgraded to 'IND A1+' from 'IND A1'.
Viyash Scientific Limited allotted 8,000 equity shares at Rs. 86 each under its ESOP 2020 scheme. The allotment, worth approximately ₹0.07 Crore, increases the company's paid-up equity share capital to Rs. 87.37 Crore. These new shares rank pari passu with existing equity.
Viyash Scientific Ltd has been assigned an '[ICRA]AA- (Stable)' rating for its Rs. 185.00 Crore Long-term Fund Based Working Capital Facilities. This rating from ICRA Limited is higher than the company's previous long-term rating of 'IND A/Positive' issued by India Ratings & Research, reflecting improved creditworthiness.
Viyash Scientific Limited has appointed Mr. Amit Jain (Carlyle India Head) and Mr. Abhiroop Jayanthi (Carlyle Managing Director) as Non-Executive Non-Independent Directors effective April 22, 2026. These appointments bring significant private equity and healthcare sector expertise to the board, following a board meeting held on the same day.
Viyash Scientific Limited has appointed Mr. Amit Jain and Mr. Abhiroop Jayanthi as Non-Executive Non-Independent Directors effective April 22, 2026. Both appointees represent Carlyle India and bring extensive private equity and healthcare sector expertise to the board. These appointments followed a board meeting held on the same day.
Viyash Scientific Limited appointed Mr. Amit Jain and Mr. Abhiroop Jayanthi as Additional Directors representing the Carlyle Group. The Board also approved a revised ESOP 2026 pool of 1,30,98,000 stock options. These appointments strengthen the company's leadership and strategic ties with Carlyle.
Viyash Scientific Limited (formerly Sequent Scientific Limited) has updated its corporate website to www.viyash.com and its domain to @viyash.com. Consequently, the investor relations email has changed to investorrelations@viyash.com. These changes follow the company's name change and are effective immediately for all official regulatory communications.
Viyash Scientific Limited submitted its quarterly compliance certificate under Regulation 74(5) for the period ended March 31, 2026. Issued by KFin Technologies, the certificate confirms the processing of securities dematerialization and rematerialization requests. This is a routine regulatory filing with no material impact on business operations or financial performance.
Viyash Scientific Limited allotted 16,667 equity shares at Rs. 86 per share under its 2020 ESOP plan. This issuance increases the company's paid-up equity capital to Rs. 87.37 Crore. The allotment follows an April 02, 2026, resolution by the Nomination and Remuneration Committee.